Cargando…

Nanostructured Non-Ionic Surfactant Carrier-Based Gel for Topical Delivery of Desoximetasone

Psoriasis is a chronic autoimmune skin disease impacting the population globally. Pharmaceutical products developed to combat this condition commonly used in clinical settings are IV bolus or oral drug delivery routes. There are some major challenges for effectively developing new dosage forms for t...

Descripción completa

Detalles Bibliográficos
Autores principales: Shah, Parinbhai, Goodyear, Benjamin, Dholaria, Nirali, Puri, Vinam, Michniak-Kohn, Bozena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7913730/
https://www.ncbi.nlm.nih.gov/pubmed/33546426
http://dx.doi.org/10.3390/ijms22041535
_version_ 1783656869482463232
author Shah, Parinbhai
Goodyear, Benjamin
Dholaria, Nirali
Puri, Vinam
Michniak-Kohn, Bozena
author_facet Shah, Parinbhai
Goodyear, Benjamin
Dholaria, Nirali
Puri, Vinam
Michniak-Kohn, Bozena
author_sort Shah, Parinbhai
collection PubMed
description Psoriasis is a chronic autoimmune skin disease impacting the population globally. Pharmaceutical products developed to combat this condition commonly used in clinical settings are IV bolus or oral drug delivery routes. There are some major challenges for effectively developing new dosage forms for topical use: API physicochemical nature, the severity of the disease state, and low bioavailability present challenges for pharmaceutical product developers. For non-severe cases of psoriasis, topical drug delivery systems may be preferred or used in conjunction with oral or parenteral therapy to address local symptoms. Elastic vesicular systems, termed “niosomes”, are promising drug delivery vehicles developed to achieve improved drug delivery into biological membranes. This study aimed to effectively incorporate a corticosteroid into the niosomes for improving the drug bioavailability of desoximetasone, used to treat skin conditions via topical delivery. Niosomes characterization measurements were drug content, pH, spreadability, specific gravity, content uniformity, rheology, and physicochemical properties. Formulations used a topical gelling agent, Carbomer 980 to test for in vitro skin permeation testing (IVPT) and accelerated stability studies. The developed niosomal test gel provided approximately 93.03 ± 0.23% to 101.84 ± 0.11% drug content with yield stresses ranging from 16.12 to 225.54 Pa. The permeated amount of desoximetasone from the niosomal gel after 24 h was 9.75 ± 0.44 µg/cm(2) compared to 24.22 ± 4.29 µg/cm(2) released from the reference gel tested. Furthermore, a drug retention study compared the test gel to a reference gel, demonstrating that the skin retained 30.88 ng/mg of desoximetasone while the reference product retained 26.01 ng/mg. A controlled drug release profile was obtained with a niosomal formulation containing desoximetasone for use in a topical gel formulation showing promise for potential use to treat skin diseases like psoriasis.
format Online
Article
Text
id pubmed-7913730
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-79137302021-02-28 Nanostructured Non-Ionic Surfactant Carrier-Based Gel for Topical Delivery of Desoximetasone Shah, Parinbhai Goodyear, Benjamin Dholaria, Nirali Puri, Vinam Michniak-Kohn, Bozena Int J Mol Sci Article Psoriasis is a chronic autoimmune skin disease impacting the population globally. Pharmaceutical products developed to combat this condition commonly used in clinical settings are IV bolus or oral drug delivery routes. There are some major challenges for effectively developing new dosage forms for topical use: API physicochemical nature, the severity of the disease state, and low bioavailability present challenges for pharmaceutical product developers. For non-severe cases of psoriasis, topical drug delivery systems may be preferred or used in conjunction with oral or parenteral therapy to address local symptoms. Elastic vesicular systems, termed “niosomes”, are promising drug delivery vehicles developed to achieve improved drug delivery into biological membranes. This study aimed to effectively incorporate a corticosteroid into the niosomes for improving the drug bioavailability of desoximetasone, used to treat skin conditions via topical delivery. Niosomes characterization measurements were drug content, pH, spreadability, specific gravity, content uniformity, rheology, and physicochemical properties. Formulations used a topical gelling agent, Carbomer 980 to test for in vitro skin permeation testing (IVPT) and accelerated stability studies. The developed niosomal test gel provided approximately 93.03 ± 0.23% to 101.84 ± 0.11% drug content with yield stresses ranging from 16.12 to 225.54 Pa. The permeated amount of desoximetasone from the niosomal gel after 24 h was 9.75 ± 0.44 µg/cm(2) compared to 24.22 ± 4.29 µg/cm(2) released from the reference gel tested. Furthermore, a drug retention study compared the test gel to a reference gel, demonstrating that the skin retained 30.88 ng/mg of desoximetasone while the reference product retained 26.01 ng/mg. A controlled drug release profile was obtained with a niosomal formulation containing desoximetasone for use in a topical gel formulation showing promise for potential use to treat skin diseases like psoriasis. MDPI 2021-02-03 /pmc/articles/PMC7913730/ /pubmed/33546426 http://dx.doi.org/10.3390/ijms22041535 Text en © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Shah, Parinbhai
Goodyear, Benjamin
Dholaria, Nirali
Puri, Vinam
Michniak-Kohn, Bozena
Nanostructured Non-Ionic Surfactant Carrier-Based Gel for Topical Delivery of Desoximetasone
title Nanostructured Non-Ionic Surfactant Carrier-Based Gel for Topical Delivery of Desoximetasone
title_full Nanostructured Non-Ionic Surfactant Carrier-Based Gel for Topical Delivery of Desoximetasone
title_fullStr Nanostructured Non-Ionic Surfactant Carrier-Based Gel for Topical Delivery of Desoximetasone
title_full_unstemmed Nanostructured Non-Ionic Surfactant Carrier-Based Gel for Topical Delivery of Desoximetasone
title_short Nanostructured Non-Ionic Surfactant Carrier-Based Gel for Topical Delivery of Desoximetasone
title_sort nanostructured non-ionic surfactant carrier-based gel for topical delivery of desoximetasone
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7913730/
https://www.ncbi.nlm.nih.gov/pubmed/33546426
http://dx.doi.org/10.3390/ijms22041535
work_keys_str_mv AT shahparinbhai nanostructurednonionicsurfactantcarrierbasedgelfortopicaldeliveryofdesoximetasone
AT goodyearbenjamin nanostructurednonionicsurfactantcarrierbasedgelfortopicaldeliveryofdesoximetasone
AT dholarianirali nanostructurednonionicsurfactantcarrierbasedgelfortopicaldeliveryofdesoximetasone
AT purivinam nanostructurednonionicsurfactantcarrierbasedgelfortopicaldeliveryofdesoximetasone
AT michniakkohnbozena nanostructurednonionicsurfactantcarrierbasedgelfortopicaldeliveryofdesoximetasone